CEO Markus Warmuth (Monte Rosa)
Monte Rosa rakes in $96M Series B as it prepares 'molecular glue' platform for IND-enabling studies
About four months after completing an extension to its Series A, Monte Rosa Therapeutics is putting its next foot forward with another heap of cash …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
